Abbott Gets a Brass Ring
Chiron Corp. has licensed rights to HCV nucleic acid diagnostics to Abbott Laboratories on a semi-exclusive basis for use in clinical applications, excluding blood banking. HCV is one of the most coveted diagnostics tests and Chiron, which holds the patent on has been very cautious about licensing rights; so far, it has licensed immunoassay rights to two companies, two for blood banking only, and nucleic acid rights to Bayer AG. l
You may also be interested in...
With AIDS and HCV under control, companies large and small are looking to protect the blood supply from a range of known and as yet unknown pathogens, which pose potential threats. Near-term attention is focusing on emerging pathogen inactivation technologies, which are moving closer to the clinic, even as questions linger about their cost effectiveness and toxicity.
The company is optimistic about a significant portion of eligible patients opting for its newly approved long-acting HIV therapy over daily, oral antiviral therapy.